Loading market dashboard
Companhia Siderúrgica Nacional
SIDBasic MaterialsNYSEBR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
SciBase Announces New Research Highlighting Nevisense's Potential in Detecting Age-Related Skin Barrier Changes PR Newswire
SID incurs a loss in Q1 as softer steel demand, imports and weather drag revenues, though EBITDA rises and margins improve.
National Steel NYSE: SID, the Brazilian steelmaker known as CSN, reported higher first-quarter 2026 adjusted EBITDA despite heavy rainfall, a stronger Brazilian real and continued pressure from steel imports in the early part of the year, executives said on the company's earnings call.
Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript
New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and clinical results SID data included in late-breaking oral presentation; company to review data at investor and analyst meeting today at 1:30 pm ET (12:30 pm CT) SOUTH SAN FRANCISCO, Calif.
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois.
SEOUL, South Korea, May 4, 2026 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that it is unveiling its next-generation OLED technologies at SID Display Week 2026, further strengthening its OLED leadership. During the exhibition, held at the Los Angeles Convention Center from May 5 to 7, LG Display will present OLED display solutions optimized for the AI era under the theme, "OLED Evolution for the AI Era.
SÃO PAULO, April 30, 2026 /PRNewswire/ -- Companhia Siderúrgica Nacional (NYSE: SID and B3: CSNA3) ("CSN") has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 30, 2026. Shareholders and holders of American depositary shares representing CSN's shares have the ability to, upon request to CSN's Investor Relations Department, receive a hard copy of CSN's complete audited financial statements, free of charge, within a reasonable period of time following the request.
Two oral presentations including late-breaker at SID Data will cover Phase 1 clinical trial of soquelitinib for atopic dermatitis, including new immunologic and biomarker data supporting drug-free remissions Investor and analyst meeting scheduled for 1:30 pm ET (12:30 pm CT) on May 14, 2026 Company to report first quarter 2026 financial results on May 7, 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, announced today that it will host an in-person and virtual investor and analyst meeting on May 14, 2026 to highlight soquelitinib data being presented at the Society for Investigative Dermatology (SID) Annual Meeting, which is taking place May 13-16, 2026 in Chicago.
Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript
